Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-90010 + Vinorelbine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-90010 | CC 90010|CC90010|BMS-986378|BMS 986378|BMS986378 | BET Inhibitor (Pan) 32 | CC-90010 is a reversible, small molecule drug that binds to BD2 (bromodomain 2) of BET proteins and inhibits interaction with acetylated histones, potentially resulting in disrupted expression of genes that promote cell growth, and inhibition of proliferation of tumor cells overexpressing BET proteins (PMID: 32240793). | |
Vinorelbine | Navelbine | Vinorelbin | Antimicrotubule Agent 14 | Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06137651 | Phase I | CC-90010 + Vinorelbine | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | Withdrawn | USA | 0 |